Deutsche Märkte geschlossen

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
66,61+0,95 (+1,45%)
Ab 11:45AM EDT. Markt geöffnet.

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
http://arrowheadpharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter232

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Christopher R. AnzaloneCEO, Pres & Director1,61M3,07M1969
Mr. Kenneth A. MyszkowskiChief Financial Officer690,3k4,25M1966
Dr. Bruce D. GivenAdvisor486,31k5,93M1954
Dr. Javier San MartinChief Medical Officer673,57kN/A1965
Mr. James HassardChief Commercial Officer488,3kN/A1967
Dr. Mark M. DavisFounder and Founder & Director of Insert Therapeutics Inc & CalandoN/AN/AN/A
Ms. Jane DavidsonHead of HR & Admin., VP and Corp. Sec.N/AN/AN/A
Dr. Vincent AnzaloneVP of Investor RelationsN/AN/AN/A
Mr. Patrick O'BrienChief Compliance Officer, Gen. Counsel & Corp. Sec.N/AN/A1964
Mr. Howard LovyDirector of CommunicationsN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Corporate Governance

Arrowhead Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 30. April 2021, lautet 4. Die grundlegenden Scores sind Audit: 2, Vorstand: 8, Shareholderrechte: 1, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.